Search results
Could Editas Medicine Become the Next CRISPR Therapeutics?
Motley Fool via Yahoo Finance· 3 months agoEditas Medicine (NASDAQ: EDIT) and CRISPR Therapeutics (NASDAQ: CRSP) share more than a few...
Editas Medicine, Inc. (NASDAQ:EDIT) Q4 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 2 months agoEditas Medicine, Inc. (NASDAQ:EDIT) Q4 2023 Earnings Call Transcript February 28, 2024 Editas...
Is Editas Medicine Stock a Buy Now?
Motley Fool· 10 months agoInvestors tend to move away from somewhat speculative stocks when the economic going gets rough. Editas Medicine's most advanced candidate is EDIT-301,...
Where Will Editas Medicine Be in 1 Year?
Motley Fool· 1 year agoGene-editing specialist Editas Medicine (NASDAQ: EDIT) fits the bill, which is why the company's shares have plunged this year. Could this be what's in...
Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics
Motley Fool via Yahoo Finance· 4 months agoInvesting in cutting-edge companies is a bit riskier than investing in tried-and-tested players, but...
Will Editas Medicine (NASDAQ:EDIT) Spend Its Cash Wisely?
Simply Wall St. via Yahoo Finance· 2 years agoJust because a business does not make any money, does not mean that the stock will go down. For...
Editas Medicine, Inc. (NASDAQ:EDIT) is a favorite amongst institutional investors who own 69%
Simply Wall St. via Yahoo Finance· 5 months agoKey Insights Institutions' substantial holdings in Editas Medicine implies that they have...
Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?
Simply Wall St. via Yahoo Finance· 2 years agoJust because a business does not make any money, does not mean that the stock will go down. For...
Can This Experimental Gene Therapy Be Enough to Lift Editas Medicine in the Future?
Motley Fool· 1 year agoEditas Medicine (NASDAQ: EDIT) sits at the bleeding edge of biotech's hottest field, gene editing to...
Why Editas Medicine Stock Soared as Much as 42% Higher This Week
Motley Fool via Yahoo Finance· 2 months agoShares of Editas Medicine (NASDAQ: EDIT) charged sharply higher this week, soaring as much as 41.6%,...
